Overview

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed. This trial will compare the rate of gastric ulcer by endoscopy over three months in patients with knee osteoarthritis, with patients receiving either LT-NS001 at a dose which provides comparable dose levels of Naproxen, or Naprosyn® 500mg (an approved treatment for OA).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Logical Therapeutics
Collaborator:
PRA Health Sciences
Treatments:
Naproxen